rs780095 — GCKR GCKR Glucose-Lipid Regulation Variant

GCKR Enhancer Variant — Regulating the Hepatic Glucose-Lipid Switch

The liver makes a continuous choice: phosphorylate incoming glucose (clearing it from the bloodstream) or conserve it. The enzyme doing the phosphorylating is glucokinase (GCK), and its gatekeeper is glucokinase regulatory protein (GKRP)¹¹ glucokinase regulatory protein (GKRP)
Encoded by the GCKR gene on chromosome 2; shuttles glucokinase in and out of the nucleus in response to fasting and fed-state signals, acting as the liver's primary brake on glucose uptake. rs780095 sits inside an intron of GCKR at a liver-specific enhancer element — a genomic switch that determines how much GKRP protein the liver produces.

This variant is mechanistically distinct from the better-characterized GCKR coding variant rs1260326 (P446L), which impairs GKRP's sensitivity to fructose-6-phosphate. rs780095 instead regulates GKRP protein abundance: the G allele sits on a three-SNP haplotype (rs780094-C / rs780095-G / rs780096-G) that drives higher GCKR expression and stronger FOXA2 transcription factor binding²² higher GCKR expression and stronger FOXA2 transcription factor binding
López Rodríguez et al. 2017 confirmed this in 132 heterozygous liver biopsy donors from the Kuopio Obesity Surgery cohort (KOBS); CGG haplotype showed higher H3K27Ac histone marks and FOXA2 binding relative to the TAC haplotype.

The Mechanism

FOXA2 is a hepatocyte-enriched transcription factor that coordinates fasting-state gene programs — including GKRP expression. The rs780095-G allele disrupts a MAFK transcription factor binding motif³³ MAFK transcription factor binding motif
MAF basic leucine zipper transcription factors regulate liver gene expression; rs780095 falls within a predicted MAFK binding site whose integrity differs between the G and A alleles within the intronic enhancer, shifting the regulatory balance toward stronger FOXA2-driven GCKR transcription. More GKRP protein in the hepatocyte means glucokinase spends more time sequestered in the nucleus and less time free in the cytoplasm phosphorylating glucose.

The downstream metabolic consequences follow directly: more GKRP inhibition → less hepatic glucose phosphorylation → slightly higher fasting glucose. Conversely, with glucokinase activity suppressed, less glucose enters the glycolytic pathway, less malonyl-CoA is generated, and hepatic de novo lipogenesis is partially braked. This produces a mirror image of the P446L trade-off: the G allele of rs780095 nudges fasting glucose upward while modestly protecting against GKRP-driven triglyceride overproduction — at least through the expression pathway.

The Evidence

The regulatory role of rs780095 was characterized in a 2017 Genome Medicine study⁴⁴ 2017 Genome Medicine study
López Rodríguez M, Kaminska D, Lappalainen K, Pihlajamäki J, Kaikkonen MU, Laakso M; Genome Medicine 9:63, 2017 using human liver biopsies from 132 individuals heterozygous for the rs780094-rs780095-rs780096 haplotype. In HepG2 hepatoma cells and primary mouse hepatocytes, the CGG haplotype (carrying rs780095-G) showed significantly greater FOXA2-induced transcriptional activity than the TAC haplotype. Allele-specific eQTL analysis in the human liver biopsies confirmed higher GCKR mRNA expression from the CGG haplotype allele.

At the metabolic phenotype level, the closely linked rs780094 and rs1260326 have been studied in tens of thousands of individuals. Orho-Melander et al. 2008⁵⁵ Orho-Melander et al. 2008
Fine-mapping study of the GCKR locus in >45,000 individuals across 12 independent cohorts; Nature Genetics 2008 established that the rs780094-T haplotype (TAC, which carries rs780095-A) is the TG-raising variant, associated with higher triglycerides (P=3×10⁻⁵⁶), lower fasting glucose (P=1×10⁻¹³), and elevated CRP (P=5×10⁻⁵). The ARIC Study (n=14,889)⁶⁶ ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; prospective cardiovascular cohort quantified the per-allele effect at −1.93 mg/dl fasting glucose and +0.16 mmol/l triglycerides for the linked rs1260326-T allele.

A meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)⁷⁷ meta-analysis of gestational diabetes studies (1,122 women; 267 GDM cases)
Jamalpour et al. 2018, Gene found that the rs780094-C allele (co-inherited with rs780095-G on the CGG haplotype) carries elevated GDM risk (OR 1.32, 95% CI 1.14–1.52), consistent with the glucose-raising effect of the high-GKRP-expression haplotype.

Practical Actions

The actionable interventions for the G allele centre on managing slightly elevated fasting glucose risk. Unlike the closely related rs1260326 P446L effect — where the triglyceride burden drives the main action items — the rs780095 G allele's primary concern is sustained mild elevation of hepatic glucose output through amplified GCK inhibition. Monitoring fasting glucose and HbA1c provides early detection, and dietary strategies that reduce hepatic glycolytic substrate (limiting refined carbohydrates at meals) directly address the elevated GKRP activity. Insulin sensitivity markers (fasting insulin, HOMA-IR) are also worth tracking because reduced hepatic glucose uptake can eventually contribute to compensatory hyperinsulinaemia.

Interactions

rs780095 is in a three-SNP haplotype with rs780094 and rs780096. The closely linked rs1260326 (P446L, r²=0.93 with rs780094) is the functional coding variant that drives the complementary TG-raising/glucose-lowering signal — individuals who carry the P446L T allele likely carry rs780095-A on the same haplotype and have a distinct metabolic profile (lower glucose, higher TG). The GCK promoter variant rs1799884 acts within the same hepatic glucose-sensing network; additive effects on fasting glucose have been reported for GCKR and GCK variants in combination. The PNPLA3 rs738409 G allele compounds hepatic fat risk for carriers of the TG-raising TAC haplotype (rs780095-A side), not the glucose-raising CGG haplotype side.